Improving cancer immunotherapy through nanotechnology

Immunity, Inflammation, and Cancer

Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755 · see citing works

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · see citing works

Understanding the tumor immune microenvironment (TIME) for effective therapy

Binnewies, M., Roberts, E. W., Kersten, K., Chan, V., Fearon, D. F., Merad, M., Coussens, L. M., Gabrilovich, D. I., Ostrand-Rosenberg, S., Hedrick, C. C., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0014-x · Cited by 6,145 · see citing works

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030 · see citing works

Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia

Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735 · see citing works

Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy

Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588 · see citing works

Analysis of nanoparticle delivery to tumours

Wilhelm, S., Tavares, A. J., Dai, Q., Ohta, S., Audet, J., Dvorak, H. F., & Chan, W. C. W. (2016) · Nature Reviews Materials · doi:10.1038/natrevmats.2016.14 · Cited by 5,218 · see citing works

mRNA vaccines — a new era in vaccinology

Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667 · see citing works

Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656 · see citing works

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448 · see citing works

Tumor mutational burden and response rate to PD-1 inhibition

Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230 · see citing works

Delivery technologies for cancer immunotherapy

Riley, R., June, C. H., Langer, R., & Mitchell, M. J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0006-z · Cited by 2,621 · see citing works

Adoptive cell transfer as personalized immunotherapy for human cancer

Rosenberg, S. A., & Restifo, N. P. (2015) · Science · doi:10.1126/science.aaa4967 · Cited by 2,492 · see citing works

mRNA-based therapeutics--developing a new class of drugs

Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474 · see citing works

5'-Triphosphate RNA Is the Ligand for RIG-I

Hornung, V., Ellegast, J., Kim, S., Brzózka, K., Jung, A., Kato, H., Poeck, H., Akira, S., Conzelmann, K.-K., Schlee, M., et al. (2006) · Science · doi:10.1126/science.1132505 · Cited by 2,474 · see citing works

Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy

Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,771 · see citing works

Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y., Dudley, M. E., Wunderlich, J. R., Somerville, R. P. T., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,710 · see citing works

Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas

Schuster, S., Svoboda, J., Chong, E., Nasta, S., Mato, A., Anak, Ö., Brogdon, J., Pruteanu-Malinici, I., Bhoj, V. G., Landsburg, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708566 · Cited by 1,599 · see citing works

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

Corrales, L., Glickman, L. H., McWhirter, S. M., Kanne, D. B., Sivick, K. E., Katibah, G. E., Woo, S.-R., Lemmens, E., Banda, T., Leong, J. J., et al. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.04.031 · Cited by 1,560 · see citing works

Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy

Ribas, A., Dummer, R., Puzanov, I., VanderWalde, A., Andtbacka, R. H. I., Michielin, O., Olszanski, A. J., Malvehy, J., Cebon, J., Fernandez, E., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.027 · Cited by 1,520 · see citing works

Exploiting lymphatic transport and complement activation in nanoparticle vaccines

Reddy, S. T., van der Vlies, A. J., Simeoni, E., Angeli, V., Randolph, G. J., O’Neil, C. P., Lee, L. K., Swartz, M. A., & Hubbell, J. A. (2007) · Nature Biotechnology · doi:10.1038/nbt1332 · Cited by 1,355 · see citing works

Inflammation and cancer: advances and new agents

Crusz, S. M., & Balkwill, F. R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.105 · Cited by 1,184 · see citing works

A Structured Tumor-Immune Microenvironment in Triple Negative Breast Cancer Revealed by Multiplexed Ion Beam Imaging

Keren, L., Bosse, M., Marquez, D., Angoshtari, R., Jain, S., Varma, S., Yang, S.-R., Kurian, A., Van Valen, D., West, R., et al. (2018) · Cell · doi:10.1016/j.cell.2018.08.039 · Cited by 1,183 · see citing works

The future of cancer treatment: immunomodulation, CARs and combination immunotherapy

Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 1,151 · see citing works

PD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumors

Gros, A., Robbins, P. F., Yao, X., Li, Y. F., Turcotte, S., Tran, E., Wunderlich, J. R., Mixon, A., Farid, S., Dudley, M. E., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci73639 · Cited by 1,113 · see citing works

Multiplexed ion beam imaging of human breast tumors

Angelo, M., Bendall, S. C., Finck, R., Hale, M. B., Hitzman, C., Borowsky, A. D., Levenson, R. M., Lowe, J. B., Liu, S. D., Zhao, S., et al. (2014) · Nature Medicine · doi:10.1038/nm.3488 · Cited by 1,108 · see citing works

TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy

Rodell, C. B., Arlauckas, S. P., Cuccarese, M. F., Garris, C. S., Li, R., Ahmed, M. S., Kohler, R. H., Pittet, M. J., & Weissleder, R. (2018) · Nature Biomedical Engineering · doi:10.1038/s41551-018-0236-8 · Cited by 1,099 · see citing works

The Principles of Engineering Immune Cells to Treat Cancer

Lim, W. A., & June, C. H. (2017) · Cell · doi:10.1016/j.cell.2017.01.016 · Cited by 1,084 · see citing works

Designer vaccine nanodiscs for personalized cancer immunotherapy

Kuai, R., Ochyl, L. J., Bahjat, K. S., Schwendeman, A. A., & Moon, J. J. (2016) · Nature Materials · doi:10.1038/nmat4822 · Cited by 1,061 · see citing works

The Role of Mechanical Forces in Tumor Growth and Therapy

Jain, R. K., Martin, J. D., & Stylianopoulos, T. (2014) · Annual Review of Biomedical Engineering · doi:10.1146/annurev-bioeng-071813-105259 · Cited by 1,044 · see citing works

In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment

Chen, Q., Wang, C., Zhang, X., Chen, G., Hu, Q., Li, H., Wang, J., Wen, D., Zhang, Y., Lü, Y., et al. (2018) · Nature Nanotechnology · doi:10.1038/s41565-018-0319-4 · Cited by 1,019 · see citing works

Systemic Immunity Is Required for Effective Cancer Immunotherapy

Spitzer, M. H., Carmi, Y., Reticker-Flynn, N. E., Kwek, S. S., Madhireddy, D., Martins, M. M., Gherardini, P. F., Prestwood, T. R., Chabon, J., Bendall, S. C., et al. (2017) · Cell · doi:10.1016/j.cell.2016.12.022 · Cited by 963 · see citing works

Structure-based programming of lymph-node targeting in molecular vaccines

Liu, H., Moynihan, K. D., Zheng, Y., Szeto, G. L., Li, A. V., Huang, B., Egeren, D. V., Park, C., & Irvine, D. J. (2014) · Nature · doi:10.1038/nature12978 · Cited by 949 · see citing works

A STING-activating nanovaccine for cancer immunotherapy

Luo, M., Wang, H., Wang, Z., Cai, H., Lu, Z., Li, Y., Du, M., Huang, G., Wang, C., Chen, X., et al. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.52 · Cited by 904 · see citing works

Progress in tumor-associated macrophage (TAM)-targeted therapeutics

Ngambenjawong, C., Gustafson, H. H., & Pun, S. H. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.04.010 · Cited by 843 · see citing works

Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients

Gros, A., Parkhurst, M. R., Tran, E., Pasetto, A., Robbins, P. F., Ilyas, S., Prickett, T. D., Gartner, J. J., Crystal, J. S., Roberts, I. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4051 · Cited by 830 · see citing works

Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging

Bartlett, D. W., Su, H. C., Hildebrandt, I. J., Weber, W., & Davis, M. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707461104 · Cited by 808 · see citing works

A Pilot Trial Using Lymphocytes Genetically Engineered with an NY-ESO-1–Reactive T-cell Receptor: Long-term Follow-up and Correlates with Response

Robbins, P. F., Kassim, S. H., Tran, T. L. N., Crystal, J. S., Morgan, R. A., Feldman, S. A., Yang, J. C., Dudley, M. E., Wunderlich, J. R., Sherry, R. M., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2708 · Cited by 807 · see citing works

In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers

Smith, T. T., Stephan, S. B., Moffett, H. F., McKnight, L. E., Ji, W., Reiman, D., Bonagofski, E., Wohlfahrt, M. E., Pillai, S. P. S., & Stephan, M. T. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.57 · Cited by 788 · see citing works

Therapeutic cell engineering with surface-conjugated synthetic nanoparticles

Stephan, M. T., Moon, J. J., Um, S. H., Bershteyn, A., & Irvine, D. J. (2010) · Nature Medicine · doi:10.1038/nm.2198 · Cited by 752 · see citing works

Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy

Shae, D., Becker, K. W., Christov, P. P., Yun, D. S., Lytton‐Jean, A. K. R., Sevimli, S., Ascano, M., Kelley, M. C., Johnson, D. B., Balko, J. M., et al. (2019) · Nature Nanotechnology · doi:10.1038/s41565-018-0342-5 · Cited by 681 · see citing works

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

Kim, K., Skora, A. D., Li, Z., Liu, Q., Tam, A. J., Blosser, R. L., Diaz, L. A., Papadopoulos, N., Kinzler, K. W., Vogelstein, B., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1410626111 · Cited by 676 · see citing works

Impact of oncogenic pathways on evasion of antitumour immune responses

Spranger, S., & Gajewski, T. F. (2018) · Nature reviews. Cancer · doi:10.1038/nrc.2017.117 · Cited by 663 · see citing works

Enhancing T cell therapy through TCR-signaling-responsive nanoparticle drug delivery

Tang, L., Zheng, Y., Melo, M. B., Mabardi, L., Castaño, A. P., Xie, Y., Li, N., Kudchodkar, S. B., Wong, H. C., Jeng, E. K., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4181 · Cited by 663 · see citing works

Anti-CD47 antibody–mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response

Tseng, D., Volkmer, J.-P., Willingham, S. B., Contreras-Trujillo, H., Fathman, J. W., Fernhoff, N. B., Seita, J., Inlay, M. A., Weiskopf, K., Miyanishi, M., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305569110 · Cited by 656 · see citing works

Highly multiplexed immunofluorescence imaging of human tissues and tumors using t-CyCIF and conventional optical microscopes

Lin, J.-R., Izar, B., Wang, S., Yapp, C., Mei, S.-L., Shah, P., Santagata, S., & Sorger, P. (2018) · eLife · doi:10.7554/elife.31657 · Cited by 631 · see citing works

<i>Ex Vivo</i> Profiling of PD-1 Blockade Using Organotypic Tumor Spheroids

Jenkins, R. W., Aref, A. R., Lizotte, P. H., Ivanova, E., Stinson, S., Zhou, C. W., Bowden, M., Deng, J., Liu, H., Miao, D., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0833 · Cited by 594 · see citing works

Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers

Scheper, W., Kelderman, S., Fanchi, L. F., Linnemann, C., Bendle, G. M., de Rooij, M. A. J., Hirt, C., Mezzadra, R., Slagter, M., Dijkstra, K. K., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0266-5 · Cited by 568 · see citing works

Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method

Lin, J., Fallahi‐Sichani, M., & Sorger, P. K. (2015) · Nature Communications · doi:10.1038/ncomms9390 · Cited by 562 · see citing works

Perioperative events influence cancer recurrence risk after surgery

Hiller, J. G., Perry, N. J., Poulogiannis, G., Riedel, B., & Sloan, E. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.194 · Cited by 556 · see citing works

T cell stemness and dysfunction in tumors are triggered by a common mechanism

Vodnala, S. K., Eil, R., Kishton, R. J., Sukumar, M., Yamamoto, T. N., Ha, N.-H., Lee, P.-H., Shin, M., Patel, S. J., Yu, Z., et al. (2019) · Science · doi:10.1126/science.aau0135 · Cited by 552 · see citing works

Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy

Kim, J., Li, A. W., Choi, Y., Lewin, S. A., Verbeke, C. S., Dranoff, G., & Mooney, D. J. (2014) · Nature Biotechnology · doi:10.1038/nbt.3071 · Cited by 541 · see citing works

In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy

Wang, C., Sun, W., Ye, Y., Hu, Q., Bomba, H. N., & Gu, Z. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-016-0011 · Cited by 528 · see citing works

Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses

Moynihan, K. D., Opel, C. F., Szeto, G. L., Tzeng, A., Zhu, E. F., Engreitz, J., Williams, R. T., Rakhra, K., Zhang, M. H., Rothschilds, A. M., et al. (2016) · Nature Medicine · doi:10.1038/nm.4200 · Cited by 519 · see citing works

Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial

Beatty, G. L., O’Hara, M. H., Lacey, S. F., Torigian, D. A., Nazimuddin, F., Chen, F., Kulikovskaya, I. M., Soulen, M. C., McGarvey, M., Nelson, A. M., et al. (2018) · Gastroenterology · doi:10.1053/j.gastro.2018.03.029 · Cited by 515 · see citing works

Exploiting the critical perioperative period to improve long-term cancer outcomes

Horowitz, M., Neeman, E., Sharon, E., & Ben-Eliyahu, S. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.224 · Cited by 487 · see citing works

The Next Hurdle in Cancer Immunotherapy: Overcoming the Non–T-Cell–Inflamed Tumor Microenvironment

Gajewski, T. F. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.011 · Cited by 485 · see citing works

Biomaterial-assisted targeted modulation of immune cells in cancer treatment

Wang, H., & Mooney, D. J. (2018) · Nature Materials · doi:10.1038/s41563-018-0147-9 · Cited by 471 · see citing works

Exploiting the curative potential of adoptive T‐cell therapy for cancer

Hinrichs, C. S., & Rosenberg, S. A. (2014) · Immunological Reviews · doi:10.1111/imr.12132 · Cited by 466 · see citing works

T cell‐targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity

Schmid, D., Park, C. G., Hartl, C. A., Subedi, N., Cartwright, A. N., Puerto, R. B., Zheng, Y., Maiarana, J., Freeman, G. J., Wucherpfennig, K. W., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01830-8 · Cited by 449 · see citing works

The systemic response to surgery triggers the outgrowth of distant immune-controlled tumors in mouse models of dormancy

Krall, J. A., Reinhardt, F., Mercury, O. A., Pattabiraman, D. R., Brooks, M. W., Dougan, M. L., Lambert, A. W., Bierie, B., Ploegh, H. L., Dougan, S. K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan3464 · Cited by 442 · see citing works

Biopolymer implants enhance the efficacy of adoptive T-cell therapy

Stephan, S. B., Taber, A. M., Jileaeva, I., Pegues, E. P., Sentman, C. L., & Stephan, M. T. (2014) · Nature Biotechnology · doi:10.1038/nbt.3104 · Cited by 440 · see citing works

Mechanical forces in the immune system

Huse, M. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.74 · Cited by 437 · see citing works

Injectable cryogel-based whole-cell cancer vaccines

Bencherif, S. A., Sands, R. W., Ali, O. A., Li, A. W., Lewin, S. A., Braschler, T. M., Shih, T., Verbeke, C. S., Bhatta, D. B., Dranoff, G., et al. (2015) · Nature Communications · doi:10.1038/ncomms8556 · Cited by 419 · see citing works

Nanoparticulate STING agonists are potent lymph node–targeted vaccine adjuvants

Hanson, M. C., Crespo, M. P., Abraham, W. D., Moynihan, K. D., Szeto, G. L., Chen, S. H., Melo, M. B., Mueller, S., & Irvine, D. J. (2015) · Journal of Clinical Investigation · doi:10.1172/jci79915 · Cited by 388 · see citing works

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

Marabelle, A., Kohrt, H. E. K., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J. A., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci64859 · Cited by 384 · see citing works

Scaffolds that mimic antigen-presenting cells enable ex vivo expansion of primary T cells

Cheung, A. S., Zhang, D. K. Y., Koshy, S. T., & Mooney, D. J. (2018) · Nature Biotechnology · doi:10.1038/nbt.4047 · Cited by 379 · see citing works

Efficient Nanovaccine Delivery in Cancer Immunotherapy

Zhu, G., Zhang, F., Ni, Q., Niu, G., & Chen, X. S. (2017) · ACS Nano · doi:10.1021/acsnano.7b00978 · Cited by 374 · see citing works

Eradication of spontaneous malignancy by local immunotherapy

Sagiv-Barfi, I., Czerwinski, D. K., Levy, S., Alam, I. S., Mayer, A. T., Gambhir, S. S., & Levy, R. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan4488 · Cited by 357 · see citing works

Biopolymers codelivering engineered T cells and STING agonists can eliminate heterogeneous tumors

Smith, T. T., Moffett, H. F., Stephan, S. B., Opel, C. F., Dumigan, A., Jiang, X., Pillarisetty, V. G., Pillai, S. P. S., Wittrup, K. D., & Stephan, M. T. (2017) · Journal of Clinical Investigation · doi:10.1172/jci87624 · Cited by 339 · see citing works

SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study

Ribas, A., Medina, T. M., Kummar, S., Amin, A., Kalbasi, A. K., Drabick, J. J., Barve, M. A., Daniels, G. A., Wong, D. J. L., Schmidt, E. V., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0280 · Cited by 338 · see citing works

SLC19A1 is an importer of the immunotransmitter cGAMP.

Ritchie, C., Cordova, A. F., Hess, G. T., Bassik, M. C., & Li, L. (2019) · Molecular Cell · doi:10.1016/j.molcel.2019.05.006 · Cited by 333 · see citing works

Extended release of perioperative immunotherapy prevents tumor recurrence and eliminates metastases

Park, C. G., Hartl, C., Schmid, D., Carmona, E. M., Kim, H., & Goldberg, M. S. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aar1916 · Cited by 323 · see citing works

Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40

Messenheimer, D. J., Jensen, S. M., Afentoulis, M. E., Wegmann, K. W., Feng, Z., Friedman, D. J., Gough, M. J., Urba, W. J., & Fox, B. A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2677 · Cited by 319 · see citing works

Manufacturing Validation of Biologically Functional T Cells Targeted to CD19 Antigen for Autologous Adoptive Cell Therapy

Hollyman, D., Stefanski, J., Przybylowski, M., Bartido, S. M., Bórquez-Ojeda, O., Taylor, C., Yeh, R., Capacio, V., Olszewska, M., Hosey, J., et al. (2009) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318194a6e8 · Cited by 316 · see citing works

Active targeting of chemotherapy to disseminated tumors using nanoparticle-carrying T cells

Huang, B., Abraham, W. D., Zheng, Y., Bustamante-Lopez, S. C., Luo, S., & Irvine, D. J. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa5447 · Cited by 312 · see citing works

Delivering safer immunotherapies for cancer

Milling, L. E., Zhang, Y., & Irvine, D. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.011 · Cited by 307 · see citing works

Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers

Tokatlian, T., Read, B. J., Jones, C. A., Kulp, D. W., Menis, S., Chang, J. Y. H., Steichen, J. M., Kumari, S., Allen, J. D., Dane, E. L., et al. (2018) · Science · doi:10.1126/science.aat9120 · Cited by 307 · see citing works

Depleting tumor-specific Tregs at a single site eradicates disseminated tumors

Marabelle, A., Kohrt, H. E. K., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J. A., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci73340 · Cited by 304 · see citing works

Preliminary results of the first-in-human (FIH) study of MK-1454, an agonist of stimulator of interferon genes (STING), as monotherapy or in combination with pembrolizumab (pembro) in patients with advanced solid tumors or lymphomas

Harrington, K. J., Brody, J., Ingham, M., Strauss, J., Cemerski, S., Wang, M., Tse, A., Khilnani, A., Marabelle, A., & Golan, T. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.015 · Cited by 280 · see citing works

Immunoengineering: How Nanotechnology Can Enhance Cancer Immunotherapy

Goldberg, M. S. (2015) · Cell · doi:10.1016/j.cell.2015.03.037 · Cited by 279 · see citing works

Integration of a CD19 CAR into the TCR Alpha Chain Locus Streamlines Production of Allogeneic Gene-Edited CAR T Cells

MacLeod, D. T., Antony, J., Martin, A. J., Moser, R. J., Hekele, A., Wetzel, K. J., Brown, A. E., Triggiano, M. A., Hux, J. A., Pham, C. D., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.02.005 · Cited by 278 · see citing works

Engineering and physical sciences in oncology: challenges and opportunities

Mitchell, M. J., Jain, R. K., & Langer, R. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.83 · Cited by 273 · see citing works

A nanoparticle-incorporated STING activator enhances antitumor immunity in PD-L1–insensitive models of triple-negative breast cancer

Cheng, N., Watkins-Schulz, R., Junkins, R. D., David, C. N., Johnson, B. M., Montgomery, S. A., Peine, K. J., Darr, D. B., Yuan, H., McKinnon, K. P., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.120638 · Cited by 263 · see citing works

Immunomodulatory spherical nucleic acids

Radovic‐Moreno, A. F., Chernyak, N., Mader, C. C., Nallagatla, S., Kang, R. S., Hao, L., Walker, D., Halo, T. L., Merkel, T. J., Rische, C. H., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1502850112 · Cited by 260 · see citing works

Macroscale biomaterials strategies for local immunomodulation

Dellacherie, M. O., Seo, B. R., & Mooney, D. J. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0106-3 · Cited by 259 · see citing works

Improving CART-Cell Therapy of Solid Tumors with Oncolytic Virus–Driven Production of a Bispecific T-cell Engager

Wing, A., Fajardo, C. A., Posey, A. D., Shaw, C. E., Da, T., Young, R. M., Alemany, R., June, C. H., & Guedan, S. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0314 · Cited by 253 · see citing works

In Situ Regulation of DC Subsets and T Cells Mediates Tumor Regression in Mice

Ali, O. A., Emerich, D. F., Dranoff, G., & Mooney, D. J. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000359 · Cited by 248 · see citing works

Nanoparticle anchoring targets immune agonists to tumors enabling anti-cancer immunity without systemic toxicity

Zhang, Y., Li, N., Suh, H., & Irvine, D. J. (2017) · Nature Communications · doi:10.1038/s41467-017-02251-3 · Cited by 248 · see citing works

Particle shape dependence of CD8+ T cell activation by artificial antigen presenting cells

Sunshine, J. C., Perica, K., Schneck, J. P., & Green, J. J. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.09.050 · Cited by 245 · see citing works

A carbon nanotube–polymer composite for T-cell therapy

Fadel, T. R., Sharp, F. A., Vudattu, N. K., Ragheb, R. R. T., Garyu, J., Kim, D., Hong, E., Li, N., Haller, G. L., Pfefferle, L. D., et al. (2014) · Nature Nanotechnology · doi:10.1038/nnano.2014.154 · Cited by 241 · see citing works

Magnetic Field-Induced T Cell Receptor Clustering by Nanoparticles Enhances T Cell Activation and Stimulates Antitumor Activity

Perica, K., Tu, A. A., Richter, A., Bieler, J. G., Edidin, M. A., & Schneck, J. P. (2014) · ACS Nano · doi:10.1021/nn405520d · Cited by 237 · see citing works

A humanized bone marrow ossicle xenotransplantation model enables improved engraftment of healthy and leukemic human hematopoietic cells

Reinisch, A., Thomas, D., Corces, M. R., Zhang, X., Gratzinger, D. A., Hong, W., Schallmoser, K., Strunk, D., & Majeti, R. (2016) · Nature Medicine · doi:10.1038/nm.4103 · Cited by 222 · see citing works

T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy

Sackstein, R., Schatton, T., & Barthel, S. R. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.25 · Cited by 213 · see citing works

Synapse-directed delivery of immunomodulators using T-cell-conjugated nanoparticles

Stephan, M. T., Stephan, S. B., Bak, P., Chen, J., & Irvine, D. J. (2012) · Biomaterials · doi:10.1016/j.biomaterials.2012.04.029 · Cited by 210 · see citing works

Localized Immunotherapy via Liposome-Anchored Anti-CD137 + IL-2 Prevents Lethal Toxicity and Elicits Local and Systemic Antitumor Immunity

Kwong, B., Gai, S. A., Elkhader, J. A., Wittrup, K. D., & Irvine, D. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3343 · Cited by 197 · see citing works

Targeted antibody and cytokine cancer immunotherapies through collagen affinity

Ishihara, J., Ishihara, A., Sasaki, K., Lee, S. S.-Y., Williford, J.-M., Yasui, M., Abe, H., Potin, L., Hosseinchi, P., Fukunaga, K., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau3259 · Cited by 190 · see citing works

Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery

Predina, J. D., Eruslanov, E. B., Judy, B. F., Kapoor, V., Cheng, G., Wang, L.-C., Sun, J., Moon, E. K., Fridlender, Z. G., Albelda, S. Μ., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1211850110 · Cited by 188 · see citing works

Generation of Effector Memory T Cell–Based Mucosal and Systemic Immunity with Pulmonary Nanoparticle Vaccination

Li, A. V., Moon, J. J., Abraham, W. D., Suh, H., Elkhader, J. A., Seidman, M. A., Yen, M., Im, E., Foley, M. H., Barouch, D. H., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006516 · Cited by 187 · see citing works

Nanoparticle conjugation of antigen enhances cytotoxic T-cell responses in pulmonary vaccination

Nembrini, C., Stano, A., Dane, K. Y., Ballester, M. C., van der Vlies, A. J., Marsland, B. J., Swartz, M. A., & Hubbell, J. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1104264108 · Cited by 185 · see citing works

Profiling lymphocyte interactions at the single-cell level by microfluidic cell pairing

Dura, B., Dougan, S. K., Barisa, M., Hoehl, M. M., Lo, C. T., Ploegh, H. L., & Joel Voldman, B. (2015) · Nature Communications · doi:10.1038/ncomms6940 · Cited by 185 · see citing works

Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers

Moffett, H. F., Coon, M. E., Radtke, S., Stephan, S. B., McKnight, L. E., Lambert, A. R., Stoddard, B. L., Kiem, H., & Stephan, M. T. (2017) · Nature Communications · doi:10.1038/s41467-017-00505-8 · Cited by 185 · see citing works

Synthetic immune niches for cancer immunotherapy

Weiden, J., Tel, J., & Figdor, C. G. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2017.89 · Cited by 176 · see citing works

Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy

Kwong, B., Liu, H., & Irvine, D. J. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2011.03.067 · Cited by 174 · see citing works

Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer

Bobisse, S., Genolet, R., Roberti, A., Tanyi, J. L., Racle, J., Stevenson, B. J., Iseli, C., Michel, A., Bitoux, M. L., Guillaume, P., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-03301-0 · Cited by 157 · see citing works

Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events

Ishihara, J., Fukunaga, K., Ishihara, A., Larsson, H. M., Potin, L., Hosseinchi, P., Galliverti, G., Swartz, M. A., & Hubbell, J. A. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan0401 · Cited by 155 · see citing works

Preclinical Evaluation of Allogeneic CAR T Cells Targeting BCMA for the Treatment of Multiple Myeloma

Sommer, C., Boldajipour, B. A., Kuo, T. C., Bentley, T., Sutton, J. E., Chen, A., Geng, T., Dong, H., Galetto, R., Valton, J., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.04.001 · Cited by 152 · see citing works

Biologically Inspired Design of Nanoparticle Artificial Antigen-Presenting Cells for Immunomodulation

Hickey, J. W., Vicente, F. P., Howard, G. P., Mao, H., & Schneck, J. P. (2017) · Nano Letters · doi:10.1021/acs.nanolett.7b03734 · Cited by 151 · see citing works

Enrichment and Expansion with Nanoscale Artificial Antigen Presenting Cells for Adoptive Immunotherapy

Perica, K., Bieler, J. G., Schütz, C., Varela, J. C., Douglass, J., Skora, A. D., Chiu, Y., Oelke, M., Kinzler, K. W., Zhou, S., et al. (2015) · ACS Nano · doi:10.1021/acsnano.5b02829 · Cited by 148 · see citing works

Sleeping Beauty Transposon‐mediated Engineering of Human Primary T Cells for Therapy of CD19+ Lymphoid Malignancies

Huang, X., Guo, H., Kang, J., Choi, S., Zhou, T. C., Tammana, S., Lees, C. J., Li, Z.-Z., Milone, M. C., Levine, B. L., et al. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300404 · Cited by 146 · see citing works

Translating nucleic acid-sensing pathways into therapies

Junt, T., & Barchet, W. (2015) · Nature reviews. Immunology · doi:10.1038/nri3875 · Cited by 145 · see citing works

Enhancing Adoptive Cell Therapy of Cancer through Targeted Delivery of Small-Molecule Immunomodulators to Internalizing or Noninternalizing Receptors

Zheng, Y., Tang, L., Mabardi, L., Kumari, S., & Irvine, D. J. (2017) · ACS Nano · doi:10.1021/acsnano.7b00078 · Cited by 145 · see citing works

Engineering opportunities in cancer immunotherapy

Jeanbart, L., & Swartz, M. A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508516112 · Cited by 132 · see citing works

Bioengineering Thymus Organoids to Restore Thymic Function and Induce Donor-Specific Immune Tolerance to Allografts

Fan, Y., Tajima, A., Goh, S. K., Geng, X., Gualtierotti, G., Grupillo, M., Coppola, A., Bertera, S., Rudert, W. A., Banerjee, I., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.77 · Cited by 119 · see citing works

An injectable bone marrow–like scaffold enhances T cell immunity after hematopoietic stem cell transplantation

Shah, N. J., Mao, A. S., Shih, T., Kerr, M. D., Sharda, A., Raimondo, T. M., Weaver, J. C., Vrbanac, V. D., Déruaz, M., Tager, A. M., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0017-2 · Cited by 100 · see citing works

Designing natural and synthetic immune tissues

Gosselin, E. A., Eppler, H. B., Bromberg, J. S., & Jewell, C. M. (2018) · Nature Materials · doi:10.1038/s41563-018-0077-6 · Cited by 99 · see citing works

Identifying and managing the adverse effects of immune checkpoint blockade

Winer, A., Bodor, J. N., & Borghaei, H. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.01.111 · Cited by 96 · see citing works

Redox-responsive interleukin-2 nanogel specifically and safely promotes the proliferation and memory precursor differentiation of tumor-reactive T-cells

Xie, Y., Arik, H., Wei, L., Zheng, Y., Suh, H., Irvine, D. J., & Tang, L. (2019) · Biomaterials Science · doi:10.1039/c8bm01556b · Cited by 91 · see citing works

Intratumoral rhIL‐12 administration in head and neck squamous cell carcinoma patients induces B cell activation

van Herpen, C. M. L., van der Voort, R., van der Laak, J. A. W. M., Klasen, I. S., de Graaf, A. O., van Kempen, L. C. L. T., de Vries, I. J. M., Boer, T. D., Dolstra, H., Torensma, R., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23756 · Cited by 90 · see citing works

Discovery and technology for human health

(2017) · Nature Biomedical Engineering · doi:10.1038/s41551-016-0001 · Cited by 82 · see citing works

Multiscale engineering of immune cells and lymphoid organs

Kim, S., Shah, S. B., Graney, P. L., & Singh, A. (2019) · Nature Reviews Materials · doi:10.1038/s41578-019-0100-9 · Cited by 79 · see citing works

Gel-Trapped Lymphorganogenic Chemokines Trigger Artificial Tertiary Lymphoid Organs and Mount Adaptive Immune Responses In Vivo

Kobayashi, Y., & Watanabe, T. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00316 · Cited by 72 · see citing works

Targeting myeloid cells using nanoparticles to improve cancer immunotherapy

Amoozgar, Z., & Goldberg, M. S. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.09.007 · Cited by 68 · see citing works

What, Why, Where, and When: Bringing Timing to Immuno-Oncology

Rothschilds, A. M., & Wittrup, K. D. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.11.003 · Cited by 68 · see citing works

Phase I study of intratumoral application of recombinant human tumor necrosis factor

Pfreundschuh, M. G., Steinmetz, H. T., Tüschen, R., Schenk, V., Diehl, V., & Schaadt, M. (1989) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(89)90034-5 · Cited by 66 · see citing works

Separating T Cell Targeting Components onto Magnetically Clustered Nanoparticles Boosts Activation

Kosmides, A. K., Necochea, K., Hickey, J. W., & Schneck, J. P. (2018) · Nano Letters · doi:10.1021/acs.nanolett.7b05284 · Cited by 66 · see citing works

Intralesional application of recombinant human tumor necrosis factor alpha induces local tumor regression in patients with advanced malignancies

Bartsch, H. H., Pfizenmaier, K., Schroeder, M. P., & Nagel, G. A. (1989) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(89)90021-7 · Cited by 64 · see citing works

Delivery of 5′-triphosphate RNA with endosomolytic nanoparticles potently activates RIG-I to improve cancer immunotherapy

Jacobson, M. E., Wang-Bishop, L., Becker, K. W., & Wilson, J. T. (2018) · Biomaterials Science · doi:10.1039/c8bm01064a · Cited by 62 · see citing works

Abstract CT144: Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma

Milhem, M. M., Gonzales, R., Medina, T. M., Kirkwood, J. M., Buchbinder, E. I., Mehmi, I., Niu, J., Shaheen, M. F., Weight, R. M., Margolin, K. A., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-ct144 · Cited by 56 · see citing works

Ex-vivo assessment of drug response on breast cancer primary tissue with preserved microenvironments

Muraro, M. G., Muenst, S. E., Mele, V., Quagliata, L., Iezzi, G., Tzankov, A., Weber, W. P., Spagnoli, G. C., & Soysal, S. D. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1331798 · Cited by 44 · see citing works

Adsorption of Multimeric T Cell Antigens on Carbon Nanotubes: Effect on Protein Structure and Antigen‐Specific T Cell Stimulation

Fadel, T. R., Li, N., Shah, S., Look, M., Pfefferle, L. D., Haller, G. L., Justesen, S. F. L., Wilson, C. J., & Fahmy, T. M. (2012) · Small · doi:10.1002/smll.201201684 · Cited by 42 · see citing works

A sweeter approach to vaccine design

Wilson, J. T. (2019) · Science · doi:10.1126/science.aav9000 · Cited by 33 · see citing works

Efficient magnetic enrichment of antigen-specific T cells by engineering particle properties

Hickey, J. W., Isser, A., Vicente, F. P., Warner, S. B., Mao, H., & Schneck, J. P. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.09.029 · Cited by 28 · see citing works

Engineering lymphocytes with RNAi.

Ramishetti, S., & Peer, D. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.12.002 · Cited by 28 · see citing works

Time to deliver

Mash, R. J. (2006) · South African Family Practice · doi:10.1080/20786204.2006.10873431 · Cited by 26 · see citing works

Surface engineering for lymphocyte programming

Ben‐Akiva, E., Meyer, R. A., Wilson, D. R., & Green, J. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.005 · Cited by 22 · see citing works

Order of administration of combination cytokine therapies can decouple toxicity from efficacy in syngeneic mouse tumor models

Rothschilds, A. M., Tzeng, A., Mehta, N. K., Moynihan, K. D., Irvine, D. J., & Wittrup, K. D. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1558678 · Cited by 21 · see citing works

Artificial Antigen-Presenting Cells for Immunotherapies

Siefert, A. L., Fahmy, T. M., & Kim, D. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-6646-2_21 · Cited by 10 · see citing works

Surgical wound immunotherapy

Liebers, R., & Jäger, D. (2018) · Nature Nanotechnology · doi:10.1038/s41565-018-0328-3 · Cited by 5 · see citing works

Macrophages as tools and targets in cancer therapy

Mantovani, A., Allavena, P., Marchesi, F., & Garlanda, C. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00520-5 · Cited by 1,807 · see citing works

mRNA vaccines for infectious diseases: principles, delivery and clinical translation

Chaudhary, N., Weissman, D., & Whitehead, K. A. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00283-5 · Cited by 1,555 · see citing works

The evolution of commercial drug delivery technologies

Vargason, A. M., Anselmo, A. C., & Mitragotri, S. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00698-w · Cited by 1,361 · see citing works

DNA damage response signaling pathways and targets for radiotherapy sensitization in cancer

Huang, R., & Zhou, P. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0150-x · Cited by 1,231 · see citing works

Improving cancer immunotherapy using nanomedicines: progress, opportunities and challenges

Martin, J. D., Cabral, H., Stylianopoulos, T., & Jain, R. K. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0308-z · Cited by 688 · see citing works

Immunogenic Cell Death Activates the Tumor Immune Microenvironment to Boost the Immunotherapy Efficiency

Li, Z., Lai, X., Fu, S., Ren, L. F., Cai, H., Zhang, H., Gu, Z., Ma, X., & Luo, K. (2022) · Advanced Science · doi:10.1002/advs.202201734 · Cited by 688 · see citing works

Vaccination with early ferroptotic cancer cells induces efficient antitumor immunity

Efimova, I., Catanzaro, E., der Meeren, L. V., Turubanova, V. D., Hammad, H., Mishchenko, T. A., Vedunova, M. V., Fimognari, C., Bachert, C., Coppieters, F., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001369 · Cited by 537 · see citing works

Multifunctional biomolecule nanostructures for cancer therapy

Wang, J., Li, Y., & Nie, G. (2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00315-x · Cited by 505 · see citing works

Multifunctional mesoporous silica nanoparticles for biomedical applications

Xu, B., Li, S., Shi, R., & Liu, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01654-7 · Cited by 468 · see citing works

Recent Advances in Hyperthermia Therapy‐Based Synergistic Immunotherapy

Chang, M., Hou, Z., Wang, M., Li, C., & Lin, J. (2020) · Advanced Materials · doi:10.1002/adma.202004788 · Cited by 452 · see citing works

Activatable polymer nanoagonist for second near-infrared photothermal immunotherapy of cancer

Jiang, Y., Huang, J., Xu, C., & Pu, K. (2021) · Nature Communications · doi:10.1038/s41467-021-21047-0 · Cited by 443 · see citing works

cGAS-STING pathway in cancer biotherapy

Wang, Y., Luo, J., Alu, A., Han, X., Wei, Y., & Wei, X. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01247-w · Cited by 404 · see citing works

Chemical and Biomolecular Strategies for STING Pathway Activation in Cancer Immunotherapy

Garland, K. M., Sheehy, T. L., & Wilson, J. T. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00750 · Cited by 368 · see citing works

Near-infrared photoactivated nanomedicines for photothermal synergistic cancer therapy

Sun, H., Zhang, Q., Li, J., Peng, S., Wang, X., & Cai, R. (2021) · Nano Today · doi:10.1016/j.nantod.2020.101073 · Cited by 336 · see citing works

Phenolic-enabled nanotechnology: versatile particle engineering for biomedicine

Wu, D., Zhou, J., Creyer, M. N., Yim, W., Chen, Z., Messersmith, P. B., & Jokerst, J. V. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00908c · Cited by 319 · see citing works

Nanomaterials for T-cell cancer immunotherapy

Gong, N., Sheppard, N. C., Billingsley, M. M., June, C. H., & Mitchell, M. J. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00822-y · Cited by 314 · see citing works

COVID-19 mRNA vaccines: Platforms and current developments

Szabó, G. T., Mahiny, A. J., & Vlatkovic, I. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.016 · Cited by 308 · see citing works

Molecular and nanoengineering approaches towards activatable cancer immunotherapy

Zhang, C., & Pu, K. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00773c · Cited by 301 · see citing works

Carbon-based nanozymes: Design, catalytic mechanism, and bioapplication

Sun, Y., Xu, B., Pan, X., Wang, H., Wu, Q., Li, S., Jiang, B., & Liu, H. (2022) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2022.214896 · Cited by 292 · see citing works

Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities

Shemesh, C. S., Hsu, J., Hosseini, I., Shen, B., Rotte, A., Twomey, P. L., Girish, S., & Wu, B. M. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.09.038 · Cited by 289 · see citing works

Cancer nanotechnology: current status and perspectives

Kemp, J. A., & Kwon, Y. J. (2021) · Nano Convergence · doi:10.1186/s40580-021-00282-7 · Cited by 277 · see citing works

Delivery of mRNA vaccine with a lipid-like material potentiates antitumor efficacy through Toll-like receptor 4 signaling

Zhang, H., You, X., Wang, X., Cui, L., Wang, Z., Xu, F., Li, M., Yang, Z., Liu, J., Huang, P., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2005191118 · Cited by 251 · see citing works

Advanced nanomedicines for the treatment of inflammatory diseases

Brusini, R., Varna, M., & Couvreur, P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.010 · Cited by 244 · see citing works

Chemically and Biologically Engineered Bacteria‐Based Delivery Systems for Emerging Diagnosis and Advanced Therapy

Li, Z., Wang, Y., Liu, J., Rawding, P. A., Bu, J., Hong, S., & Hu, Q. (2021) · Advanced Materials · doi:10.1002/adma.202102580 · Cited by 243 · see citing works

A Polymer Multicellular Nanoengager for Synergistic NIR‐II Photothermal Immunotherapy

Xu, C., Jiang, Y., Han, Y., Pu, K., & Zhang, R. (2021) · Advanced Materials · doi:10.1002/adma.202008061 · Cited by 235 · see citing works

The Coppery Age: Copper (Cu)‐Involved Nanotheranostics

Dong, C., Feng, W., Xu, W., Yu, L., Xiang, H., Chen, Y., & Zhou, J. (2020) · Advanced Science · doi:10.1002/advs.202001549 · Cited by 235 · see citing works

Ferroptosis-driven nanotherapeutics for cancer treatment

Shan, X., Li, S., Sun, B., Chen, Q., Sun, J., He, Z., & Luo, C. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.01.008 · Cited by 209 · see citing works

Nanoscale CaH2 materials for synergistic hydrogen-immune cancer therapy

Gong, F., Xu, J., Liu, B., Yang, N., Cheng, L., Huang, P., Wang, C., Chen, Q., Ni, C., & Liu, Z. (2021) · Chem · doi:10.1016/j.chempr.2021.11.020 · Cited by 205 · see citing works

Supramolecular Nanofibrils Formed by Coassembly of Clinically Approved Drugs for Tumor Photothermal Immunotherapy

Li, S., Zhang, W., Xing, R., Yuan, C., Xue, H., & Yan, X. (2021) · Advanced Materials · doi:10.1002/adma.202100595 · Cited by 199 · see citing works

Sheddable Prodrug Vesicles Combating Adaptive Immune Resistance for Improved Photodynamic Immunotherapy of Cancer

Gao, A., Chen, B., Gao, J., Zhou, F., Saeed, M., Hou, B., Li, Y., & Yu, H. (2019) · Nano Letters · doi:10.1021/acs.nanolett.9b04012 · Cited by 198 · see citing works

Precision-engineered metal and metal-oxide nanoparticles for biomedical imaging and healthcare applications

Truong, T. T., Mondal, S. A., Doan, V. H. M., Tak, S., Choi, J., Oh, H., Nguyen, T. D., Misra, M., Lee, B., & Oh, J. (2024) · Advances in Colloid and Interface Science · doi:10.1016/j.cis.2024.103263 · Cited by 190 · see citing works

Bioengineered nanogels for cancer immunotherapy

Ma, X., Li, S., Liu, Y., Zhang, T., Xue, P., Kang, Y., Sun, Z., & Xu, Z. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00247g · Cited by 185 · see citing works

Precision cancer sono-immunotherapy using deep-tissue activatable semiconducting polymer immunomodulatory nanoparticles

Li, J., Luo, Y., Zeng, Z., Cui, D. M., Huang, J., Xu, C., Li, L., Pu, K., & Zhang, R. (2022) · Nature Communications · doi:10.1038/s41467-022-31551-6 · Cited by 183 · see citing works

Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation

Topatana, W., Juengpanich, S., Li, S., Cao, J., Hu, J., Lee, J., Suliyanto, K., Ma, D., Zhang, B., Chen, M., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00956-5 · Cited by 182 · see citing works

A Biomimetic Aggregation‐Induced Emission Photosensitizer with Antigen‐Presenting and Hitchhiking Function for Lipid Droplet Targeted Photodynamic Immunotherapy

Xu, X., Deng, G., Sun, Z., Luo, Y., Liu, J., Yu, X., Zhao, Y., Gong, P., Liu, G., Zhang, P., et al. (2021) · Advanced Materials · doi:10.1002/adma.202102322 · Cited by 171 · see citing works

ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance

Jang, S. C., Economides, K. D., Moniz, R. J., Sia, C. L., Lewis, N. D., McCoy, C., Zi, T., Zhang, K. X., Harrison, R. A., Lim, J. Y. H., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02004-5 · Cited by 169 · see citing works

Extracellular Vesicles from Akkermansia muciniphila Elicit Antitumor Immunity Against Prostate Cancer via Modulation of CD8+ T Cells and Macrophages

Luo, Z., Xia, K., Liu, Y.-W., Liu, J., Rao, S., Hu, X., Chen, C., Xu, R., Wang, Z., & Xie, H. (2021) · International Journal of Nanomedicine · doi:10.2147/ijn.s304515 · Cited by 165 · see citing works

Extracellular vesicles in ovarian cancer chemoresistance, metastasis, and immune evasion

Tian, W., Lei, N., Zhou, J., Chen, M., Guo, R., Qin, B., Li, Y., & Chang, L. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04510-8 · Cited by 160 · see citing works

MRI-traceable theranostic nanoparticles for targeted cancer treatment

Anani, T., Rahmati, S., Nayer, S., & David, A. E. (2020) · Theranostics · doi:10.7150/thno.48811 · Cited by 157 · see citing works

Rethinking Antigen Source: Cancer Vaccines Based on Whole Tumor Cell/tissue Lysate or Whole Tumor Cell

Diao, L., & Liu, M. (2023) · Advanced Science · doi:10.1002/advs.202300121 · Cited by 156 · see citing works

The progress and perspective of nanoparticle-enabled tumor metastasis treatment

Zhang, W., Wang, F., Hu, C., Zhou, Y., Gao, H., & Hu, J. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.07.013 · Cited by 152 · see citing works

An Up‐to‐Date Review on Alginate Nanoparticles and Nanofibers for Biomedical and Pharmaceutical Applications

Dodero, A., Alberti, S., Gaggero, G., Ferretti, M., Botter, R., Vicini, S., & Castellano, M. (2021) · Advanced Materials Interfaces · doi:10.1002/admi.202100809 · Cited by 152 · see citing works

Charge‐Reversal Polymer Nano‐modulators for Photodynamic Immunotherapy of Cancer

He, S., Li, J., Cheng, P., Zeng, Z., Zhang, C., Duan, H., & Pu, K. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202106392 · Cited by 148 · see citing works

Target Reprogramming Lysosomes of CD8+ T Cells by a Mineralized Metal–Organic Framework for Cancer Immunotherapy

Zhao, Q. P., Gong, Z., Li, Z., Wang, J., Zhang, J., Zhao, Z., Zhang, P., Zheng, S., Miron, R. J., Yuan, Q., et al. (2021) · Advanced Materials · doi:10.1002/adma.202100616 · Cited by 146 · see citing works

Engineering of Living Cells with Polyphenol‐Functionalized Biologically Active Nanocomplexes

Zhao, Z., Pan, D. C., Qi, Q. M., Kim, J., Kapate, N., Sun, T., Shields, C. W., Wang, L., Wu, D., Kwon, C. J., et al. (2020) · Advanced Materials · doi:10.1002/adma.202003492 · Cited by 144 · see citing works

Reactive oxygen species-powered cancer immunotherapy: Current status and challenges

He, M., Wang, M., Xu, T., Zhang, M., Dai, H., Wang, C., Ding, D., & Zhong, Z. (2023) · Journal of Controlled Release · doi:10.1016/j.jconrel.2023.02.040 · Cited by 144 · see citing works

Fucoidan-based, tumor-activated nanoplatform for overcoming hypoxia and enhancing photodynamic therapy and antitumor immunity

Chung, C., Lu, K.-Y., Lee, W.-C., Hsu, W., Lee, W.-F., Dai, J.-Z., Shueng, P., Lin, C., & Mi, F. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120227 · Cited by 142 · see citing works

Microfluidic synthesis of lipid-based nanoparticles for drug delivery: recent advances and opportunities

Mehraji, S., & DeVoe, D. L. (2024) · Lab on a Chip · doi:10.1039/d3lc00821e · Cited by 139 · see citing works

Biomimetic and bioinspired nano‐platforms for cancer vaccine development

Feng, C., Tan, P., Nie, G., & Zhu, M. (2023) · Exploration · doi:10.1002/exp.20210263 · Cited by 138 · see citing works

Recent Advances in Cell Membrane‐Derived Biomimetic Nanotechnology for Cancer Immunotherapy

Raza, F., Zafar, H., Zhang, S., Kamal, Z., Su, J., Yuan, W., & Mingfeng, Q. (2021) · Advanced Healthcare Materials · doi:10.1002/adhm.202002081 · Cited by 135 · see citing works

Context-dependent functions of pattern recognition receptors in cancer

Man, S. M., & Jenkins, B. J. (2022) · Nature reviews. Cancer · doi:10.1038/s41568-022-00462-5 · Cited by 135 · see citing works

Toll-like receptor 9 agonists and combination therapies: strategies to modulate the tumour immune microenvironment for systemic anti-tumour immunity

Dongye, Z., Li, J., & Wu, Y. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01876-6 · Cited by 135 · see citing works

Nanoparticles-encapsulated polymeric microneedles for transdermal drug delivery

Chen, M., Quan, G., Sun, Y. H., Yang, D., Pan, X., & Wu, C. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.06.039 · Cited by 133 · see citing works

Checkpoint Nano‐PROTACs for Activatable Cancer Photo‐Immunotherapy

Zhang, C., Xu, M., He, S., Huang, J., Xu, C., & Pu, K. (2022) · Advanced Materials · doi:10.1002/adma.202208553 · Cited by 130 · see citing works

Nano-enhanced immunotherapy: Targeting the immunosuppressive tumor microenvironment

Jin, Y., Huang, Y., Ren, H., Huang, H., Lai, C., Wang, W., Tong, Z., Zhang, H., Wu, W., Liu, C., et al. (2024) · Biomaterials · doi:10.1016/j.biomaterials.2023.122463 · Cited by 129 · see citing works

Modulation of tumor microenvironment for immunotherapy: focus on nanomaterial-based strategies

Liu, Y., Guo, J., & Huang, L. (2020) · Theranostics · doi:10.7150/thno.42998 · Cited by 128 · see citing works

Recent Advances in Molecular Mechanisms of Cancer Immunotherapy

Kciuk, M., Yahya, E. B., Mohamed, M. M. I., Rashid, S., Iqbal, M. O., Kontek, R., Abdulsamad, M. A., & Allaq, A. A. (2023) · Cancers · doi:10.3390/cancers15102721 · Cited by 128 · see citing works

Tumor cell membrane enveloped aluminum phosphate nanoparticles for enhanced cancer vaccination

Gan, J., Du, G., He, C., Jiang, M., Mou, X., Xue, J., & Sun, X. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.07.008 · Cited by 125 · see citing works

Nanovaccines with cell-derived components for cancer immunotherapy

Meng, Z., Zhang, Y., Zhou, X., Ji, J., & Liu, Z. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114107 · Cited by 125 · see citing works

Theranostic nanoparticles with disease-specific administration strategies

Zhang, P., Li, Y., Tang, W., Zhao, J., Jing, L., & McHugh, K. J. (2021) · Nano Today · doi:10.1016/j.nantod.2021.101335 · Cited by 118 · see citing works

Targeting regulated cell death in tumor nanomedicines

Zeng, Q., Ma, X., Song, Y., Chen, Q., Jiao, Q., & Zhou, L. (2021) · Theranostics · doi:10.7150/thno.67932 · Cited by 118 · see citing works

Engineering Prodrug Nanomedicine for Cancer Immunotherapy

Yang, B., Gao, J., Pei, Q., Xu, H., & Yu, H. (2020) · Advanced Science · doi:10.1002/advs.202002365 · Cited by 115 · see citing works

Engineering Strategies for Immunomodulatory Cytokine Therapies: Challenges and Clinical Progress

Pires, I. S., Hammond, P. T., & Irvine, D. J. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100035 · Cited by 115 · see citing works

Leveraging self-assembled nanobiomaterials for improved cancer immunotherapy

Vincent, M. P., Navidzadeh, J. O., Bobbala, S. K. R., & Scott, E. A. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.01.006 · Cited by 115 · see citing works

Regulating trained immunity with nanomedicine

van Leent, M. M. T., Priem, B., Schrijver, D. P., de Dreu, A., Hofstraat, S. R. J., Zwolsman, R. C., Beldman, T. J., Netea, M. G., & Mulder, W. J. M. (2022) · Nature Reviews Materials · doi:10.1038/s41578-021-00413-w · Cited by 114 · see citing works

Immunogenic PANoptosis‐Initiated Cancer Sono‐Immune Reediting Nanotherapy by Iteratively Boosting Cancer Immunity Cycle

Zhou, L., Lyu, J., Liu, F., Su, Y., Feng, L., & Zhang, X. (2023) · Advanced Materials · doi:10.1002/adma.202305361 · Cited by 114 · see citing works

One‐Step Symbiosis of Bimetallic Peroxides Nanoparticles to Induce Ferroptosis/Cuproptosis and Activate cGAS‐STING Pathway for Enhanced Tumor Immunotherapy

Liu, B., Chen, X., Zhu, Y., Chen, H. H., Tan, J., Yang, Z., Li, J., Zheng, P., Feng, L., Wang, Q., et al. (2025) · Advanced Materials · doi:10.1002/adma.202500337 · Cited by 111 · see citing works

Biomimetic nanoparticles deliver mRNAs encoding costimulatory receptors and enhance T cell mediated cancer immunotherapy

Li, W., Zhang, X., Zhang, C., Yan, J., Hou, X., Du, S., Zeng, C., Zhao, W., Deng, B., McComb, D. W., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27434-x · Cited by 110 · see citing works

pH-Responsive Nanoparticles for Cancer Immunotherapy: A Brief Review

Yan, Y., & Ding, H. (2020) · Nanomaterials · doi:10.3390/nano10081613 · Cited by 108 · see citing works

Smart Nanosized Drug Delivery Systems Inducing Immunogenic Cell Death for Combination with Cancer Immunotherapy

Zhou, L., Zhang, P., Wang, H., Wang, D., & Li, Y. (2020) · Accounts of Chemical Research · doi:10.1021/acs.accounts.0c00254 · Cited by 108 · see citing works

Augmenting Immunogenic Cell Death and Alleviating Myeloid‐Derived Suppressor Cells by Sono‐Activatable Semiconducting Polymer Nanopartners for Immunotherapy

Ding, M., Zhang, Y., Yu, N., Zhou, J., Zhu, L., Wang, X., & Li, J. (2023) · Advanced Materials · doi:10.1002/adma.202302508 · Cited by 108 · see citing works

Nanotransferrin-Based Programmable Catalysis Mediates Three-Pronged Induction of Oxidative Stress to Enhance Cancer Immunotherapy

Bai, S., Lu, Z., Jiang, Y., Shi, X., Xu, D., Shi, Y., Lin, G., Liu, C., Zhang, Y., & Liu, G. (2021) · ACS Nano · doi:10.1021/acsnano.1c08619 · Cited by 104 · see citing works

Antibody-based drug delivery systems for cancer therapy: Mechanisms, challenges, and prospects

Chen, Z., Kankala, R. K., Yang, Z., Li, W., Xie, S., Li, H., Chen, A., & Zou, L. (2022) · Theranostics · doi:10.7150/thno.72594 · Cited by 104 · see citing works

Engineered Nanovaccine Targeting Clec9a+ Dendritic Cells Remarkably Enhances the Cancer Immunotherapy Effects of STING Agonist

Gou, S., Liu, W., Wang, S., Chen, G., Chen, Z., Qiu, L., Zhou, X., Wu, Y., Qi, Y., & Gao, Y. (2021) · Nano Letters · doi:10.1021/acs.nanolett.1c03243 · Cited by 103 · see citing works

Engineered extracellular vesicles as intelligent nanosystems for next-generation nanomedicine

Fan, Z., Jiang, C., Wang, Y., Wang, K., Marsh, J., Zhang, D., Chen, X., & Nie, L. (2022) · Nanoscale Horizons · doi:10.1039/d2nh00070a · Cited by 103 · see citing works

From Design to Clinic: Engineered Nanobiomaterials for Immune Normalization Therapy of Cancer

Saeed, M., Chen, F., Ye, J., Shi, Y., Lammers, T., Geest, B. G. D., Xu, Z. P., & Yu, H. (2021) · Advanced Materials · doi:10.1002/adma.202008094 · Cited by 101 · see citing works

Emerging nanomedicines of paclitaxel for cancer treatment

Chen, Q., Xu, S., Liu, S., Wang, Y., & Liu, G. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.010 · Cited by 100 · see citing works

3D Printing Scaffold Vaccine for Antitumor Immunity

Zhang, Y., Xu, J., Fei, Z., Dai, H., Fan, Q., Yang, Q., Chen, Y., Wang, B., & Wang, C. (2021) · Advanced Materials · doi:10.1002/adma.202106768 · Cited by 99 · see citing works

A prodrug hydrogel with tumor microenvironment and near-infrared light dual-responsive action for synergistic cancer immunotherapy

Ding, M., Fan, Y., Lv, Y., Liu, J., Yu, N., Kong, D., Sun, H., & Li, J. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.06.041 · Cited by 99 · see citing works

Advances in Magnetic Nanoparticle‐Mediated Cancer Immune‐Theranostics

Cheng, H., Tsao, H., Chiang, C., & Chen, S. (2020) · Advanced Healthcare Materials · doi:10.1002/adhm.202001451 · Cited by 98 · see citing works

Boosting Checkpoint Immunotherapy with Biomaterials

Liu, L., Pan, Y., Zhao, C., Huang, P., Chen, X. S., & Rao, L. (2023) · ACS Nano · doi:10.1021/acsnano.2c11691 · Cited by 96 · see citing works

Black Phosphorus Nanosheet with High Thermal Conversion Efficiency for Photodynamic/Photothermal/Immunotherapy

Xu, D., Liu, J., Wang, Y., Jian, Y., Wu, W., & Lv, R. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c00984 · Cited by 94 · see citing works

Recent Advances in Nanotechnology for the Treatment of Melanoma

Cassano, R., Cuconato, M., Calviello, G., Serini, S., & Trombino, S. (2021) · Molecules · doi:10.3390/molecules26040785 · Cited by 94 · see citing works

Targeting the Tumor Microenvironment in Colorectal Peritoneal Metastases

Ceelen, W. P., Ramsay, R. G., Narasimhan, V., Heriot, A. G., & Wever, O. D. (2020) · Trends in cancer · doi:10.1016/j.trecan.2019.12.008 · Cited by 93 · see citing works

Biosynthesis of Self‐Assembled Proteinaceous Nanoparticles for Vaccination

Pan, C., Wu, J., Qing, S., Zhang, X., Zhang, L., Yue, H., Zeng, M., Wang, B., Yuan, Z., Qiu, Y., et al. (2020) · Advanced Materials · doi:10.1002/adma.202002940 · Cited by 93 · see citing works

Sex as an important factor in nanomedicine

Hajipour, M. J., Aghaverdi, H., Serpooshan, V., Vali, H., Sheibani, S., & Mahmoudi, M. (2021) · Nature Communications · doi:10.1038/s41467-021-23230-9 · Cited by 90 · see citing works

Nanocarriers Used in Drug Delivery to Enhance Immune System in Cancer Therapy

Lôbo, G. C. N. B., Paiva, K. L. R., Silva, A. L. G., Simões, M. M., Radicchi, M. A., & Báo, S. N. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081167 · Cited by 90 · see citing works

Interventional hydrogel microsphere vaccine as an immune amplifier for activated antitumour immunity after ablation therapy

Liu, X., Zhuang, Y., Huang, W., Wu, Z., Chen, Y., Shan, Q., Zhang, Y., Wu, Z., Ding, X., Qiu, Z., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39759-w · Cited by 91 · see citing works

Lipid-based nanosystems: the next generation of cancer immune therapy

Cheng, Z., Fobian, S., Gurrieri, E., Amin, M., D’Agostino, V., Falahati, M., Zalba, S., Debets, R., Garrido, M. J., Saeed, M., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01574-1 · Cited by 90 · see citing works

Metal Oxide Nanoparticles in Therapeutic Regulation of Macrophage Functions

Dukhinova, M., Prilepskii, A. Y., Shtil, A. A., & Vinogradov, V. V. (2019) · Nanomaterials · doi:10.3390/nano9111631 · Cited by 89 · see citing works

Liposomal Cytarabine as Cancer Therapy: From Chemistry to Medicine

Salehi, B., Selamoğlu, Z., Mileski, K. S., Pezzani, R., Redaelli, M., Cho, W. C. S., Kobarfard, F., Rajabi, S., Martorell, M., Kumar, P., et al. (2019) · Biomolecules · doi:10.3390/biom9120773 · Cited by 89 · see citing works

Lymph node-targeting nanovaccines for cancer immunotherapy

Wang, Q., Wang, Z., Sun, X., Jiang, Q., Sun, B., He, Z., Zhang, S., Luo, C., & Sun, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.015 · Cited by 89 · see citing works

Nanomedicine Combats Drug Resistance in Lung Cancer

Zheng, X., Song, X.-H., Zhu, G., Pan, D., Li, H., Hu, J., Xiao, K., Gong, Q., Gu, Z., Luo, K., et al. (2023) · Advanced Materials · doi:10.1002/adma.202308977 · Cited by 88 · see citing works

Nanotechnology-enhanced immunotherapy for metastatic cancer

Zhang, P., Meng, J., Li, Y., Chen, Y., Hou, Y., Tang, W., McHugh, K. J., & Jing, L. (2021) · The Innovation · doi:10.1016/j.xinn.2021.100174 · Cited by 87 · see citing works

Emerging strategies in developing multifunctional nanomaterials for cancer nanotheranostics

Ang, M. J. Y., Chan, S. Y., Goh, Y. Y., Luo, Z., Lau, J. W., & Liu, X. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113907 · Cited by 86 · see citing works

Emerging Technologies for Local Cancer Treatment

Chua, C. Y. X., Ho, J., Demaria, S., Mauro Ferrari, B., & Grattoni, A. (2020) · Advanced Therapeutics · doi:10.1002/adtp.202000027 · Cited by 85 · see citing works

Leveraging Semiconducting Polymer Nanoparticles for Combination Cancer Immunotherapy

Wu, J., & Pu, K. (2023) · Advanced Materials · doi:10.1002/adma.202308924 · Cited by 85 · see citing works

Nanomaterials in anticancer applications and their mechanism of action - A review

Das, C. G. A., Kumar, V. G., Dhas, T. S., Karthick, V., & Kumar, C. M. V. (2022) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2022.102613 · Cited by 84 · see citing works

Upregulation of exosome secretion from tumor-associated macrophages plays a key role in the suppression of anti-tumor immunity

Zhong, W., Lu, Y., Han, X., Yang, J., Qin, Z., Zhang, W., Yu, Z., Wu, B., Liu, S., Xu, W., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.113224 · Cited by 84 · see citing works

Nano-immunotherapy: Overcoming tumour immune evasion

Guevara, M. L., Persano, F., & Persano, S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.11.010 · Cited by 83 · see citing works

Nanotechnology synergized immunoengineering for cancer

Chauhan, D. S., Dhasmana, A., Laskar, P., Prasad, R., Jain, N. K., Srivastava, R., Jaggi, M., Chauhan, S. C., & Yallapu, M. M. (2021) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2021.03.010 · Cited by 27 · see citing works

Challenges and opportunities of nanotechnology in cancer immunotherapy

Lee, D., Huntoon, K. M., Jiang, W., & Kim, B. Y. S. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90949-5.00024-3 · Cited by 8 · see citing works

The application of nanotechnology in enhancing immunotherapy for cancer treatment: current effects and perspective

Li, Y., Ayala‐Orozco, C., Rauta, P. R., & Krishnan, S. (2019) · Nanoscale · doi:10.1039/c9nr05371a · Cited by 84 · see citing works

Nano Drug Delivery System for Tumor Immunotherapy: Next-Generation Therapeutics

Zhou, L., Zou, M., Xu, Y., Lin, P., Lei, C., & Xia, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.864301 · Cited by 76 · see citing works

Nanoparticle‐Based Nanomedicines to Promote Cancer Immunotherapy: Recent Advances and Future Directions

Liu, J., Zhang, R., & Xu, Z. P. (2019) · Small · doi:10.1002/smll.201900262 · Cited by 161 · see citing works